Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma.

作者: Florin M. Selaru , Suna Wang , Jing Yin , Karsten Schulmann , Yan Xu

DOI: 10.4137/BBI.S311

关键词:

摘要: BACKGROUND AND AIMS: Because of the extremely low neoplastic progression rate in Barrett's esophagus, it is difficult to diagnose patients with concomitant adenocarcinoma early their disease course. If biomarkers existed normal squamous esophageal epithelium identify adenocarcinoma, potential applications would be far-reaching. The aim current study was global gene expression patterns capable revealing simultaneous even located remotely esophagus. METHODS: Tissues comprised epithelia from 9 8 lacking or Barrett's, and 6 esophagus alone. cDNA microarrays were performed, pattern recognition each these subgroups achieved using shrunken nearest centroid predictors. RESULTS: Our method accurately discriminated 8/8 without 6/6 alone 9/9 adenocarcinoma. Moreover, we identified genes differentially expressed between above subgroups. Thus, based on corresponding alone, our diagnosed who had CONCLUSIONS: These patterns, along individual culled them, represent for diagnosis epithelia. Genes discovered that are vs. merit further pursuit molecular genetic, functional, therapeutic interventional studies.

参考文章(53)
James C. Reynolds, Michael Waronker, Maricar Sibayan Pacquing, Rihab R. Yassin, Barrett's esophagus. Reducing the risk of progression to adenocarcinoma. Gastroenterology Clinics of North America. ,vol. 28, pp. 917- 945 ,(1999) , 10.1016/S0889-8553(05)70098-4
David J. Wong, Mary J. Emond, Reinhard Stöger, Brian J. Reid, Brian J. Reid, Michael T. Barrett, p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas Cancer Research. ,vol. 57, pp. 2619- 2622 ,(1997)
Ricky W. Johnstone, Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nature Reviews Drug Discovery. ,vol. 1, pp. 287- 299 ,(2002) , 10.1038/NRD772
G. Kouraklis, S. Theocharis, Histone deacetylase inhibitors and anticancer therapy. Current Medicinal Chemistry - Anti-cancer Agents. ,vol. 2, pp. 477- 484 ,(2002) , 10.2174/1568011023353921
Yasushi Toh, Manabu Yamamoto, Kazuya Endo, Yasuharu Ikeda, Hideo Baba, Shunji Kohnoe, Hirotoshi Yonemasu, Yoichi Hachitanda, Takeshi Okamura, Keizo Sugimachi, None, Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncology Reports. ,vol. 10, pp. 333- 338 ,(2003) , 10.3892/OR.10.2.333
F M Selaru, T Zou, Y Xu, V Shustova, J Yin, Y Mori, F Sato, S Wang, A Olaru, D Shibata, B D Greenwald, M J Krasna, J M Abraham, S J Meltzer, Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays Oncogene. ,vol. 21, pp. 475- 478 ,(2002) , 10.1038/SJ.ONC.1205111
J. N. Glickman, H. Wang, K. M. Das, R. K. Goyal, S. J. Spechler, D. Antonioli, R. D. Odze, Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: An immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45MI The American Journal of Surgical Pathology. ,vol. 25, pp. 87- 94 ,(2001) , 10.1097/00000478-200101000-00010
Philippe Guillem, V�ronique Billeret, Marie-Pierre Buisine, Jean-Fran�ois Flejou, Martine Lecomte-Houcke, Pierre Degand, Jean-Pierre Aubert, Jean-Pierre Triboulet, Nicole Porchet, Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus International Journal of Cancer. ,vol. 88, pp. 856- 861 ,(2000) , 10.1002/1097-0215(20001215)88:6<856::AID-IJC3>3.0.CO;2-D
Geoffrey A.M. Neale, Rakesh Goorha, James W. Davenport, Elma R. Fernandes, Loleta D. Harris, The Mouse Mitotic Checkpoint Gene Bub1b, a Novel Bub1 Family Member, Is Expressed in a Cell Cycle-Dependent Manner Genomics. ,vol. 55, pp. 113- 117 ,(1999) , 10.1006/GENO.1998.5629
B REID, D LEVINE, G LONGTON, P BLOUNT, P RABINOVITCH, Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. The American Journal of Gastroenterology. ,vol. 95, pp. 1669- 1676 ,(2000) , 10.1016/S0002-9270(00)00988-6